OKYO Pharma Ltd

OKYO Pharma insider report: CERRONE GABRIELE M keeps a 10‑million‑share stake, valuing his holding at ~$17M. The move signals confidence in pre‑clinical plans and a potential price rally when key milestones hit.

Insider confidence fuels OKYO Pharma’s eye‑disease pipeline—Jacob Gary S. retains 108,920 shares and options, signaling potential milestones and market upside despite a current price‑sentiment lag.